*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
Alnylam Assist® is experienced in providing support services to patients on OXLUMO® (lumasiran)
When you and your doctor choose to begin treatment with OXLUMO and to enroll in Alnylam Assist®, the next step is to complete the Start Form together.
Your doctor will submit the form to Alnylam Assist®. Upon receipt of the Start Form, an Alnylam Case Manager will reach out to you and your doctor within 2 business days.
Experienced Team Members
An Alnylam Case Manager
When you and your healthcare provider choose to begin treatment with OXLUMO, you will be partnered with an Alnylam Case Manager. Case Managers are trained professionals whose expertise is in helping patients get started on treatment and providing product support.
- Helping you get started on treatment
- Understanding your insurance benefits
- Providing you with product support throughout your treatment
- Determining your eligibility for financial assistance*
An Alnylam Patient Education Liaison (PEL)
A PEL can help
The purpose of the PELs program is to provide education for patients, their families, and caregivers. PELs have a background in nursing and experience in educating patients and families about PH1 and providing information about treatment with OXLUMO.
They can help:
- Support you with understanding PH1
- Explain how OXLUMO works
- Answer questions about treatment with OXLUMO
- Connect you with additional resources
PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.
PELs do not provide medical care or advice. All diagnosis and treatment decisions should be made by you and your doctor.
For more information about Alnylam Assist® or to access downloadable materials:
Alnylam Assist® is here to help you access treatment
Alnylam offers a support program for patients receiving OXLUMO. Support services include:
Financial Assistance
Alnylam offers financial assistance programs for eligible patients. After being prescribed OXLUMO, you can talk to an Alnylam Case Manager to learn if you may be eligible.* Below are examples of two Alnylam Financial Assistance programs.
- I have insurance but have concerns about paying for OXLUMO
- Our Commercial Copay Program covers certain out-of-pocket costs for eligible patients with commercial insurance†
- I’m uninsured, or I have insurance but do not have coverage for OXLUMO
- Our Patient Assistance Program may be able to provide you with one of Alnylam's products at no cost if you’re eligible
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.
Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist® Commercial Copay Program. Out-of-pocket costs for the administration of Alnylam products will not be covered for patients residing where it is prohibited by law or where otherwise restricted.
In-home nursing support services
Depending on your doctor's recommendations and if your insurance coverage allows, you may be able to have a healthcare professional administer OXLUMO in your home.*
Reach out to Alnylam Assist® with questions.
Call: 1-833-256-2748 Monday-Friday, 8 AM-6 PM
Once you and your doctor have decided to start treatment with OXLUMO, you can call Alnylam Assist® to find out if you may be eligible for at‑home administration based on your insurance coverage.
Frequently asked questions about OXLUMO
- Who can take OXLUMO?
-
OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults. You and your doctor will determine if OXLUMO is right for you.
- What is OXLUMO and how does it work?
-
OXLUMO is a prescription medicine for the treatment of PH1 to lower oxalate in urine and blood in children and adults.
- OXLUMO targets the GO enzyme—a liver enzyme involved in making oxalate
- OXLUMO reduces levels of the GO enzyme so that less oxalate is made and sent to the kidneys
- What is the most common side effect?
-
The most common side effect is injection site reaction (redness, swelling, pain, bruising, itching, and discoloration at the site of injection). This is not the only possible side effect of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch , or call 1‑800‑FDA‑1088 .
- How is OXLUMO given?
-
OXLUMO is an injection administered by a healthcare provider. OXLUMO is injected under the skin. Injection sites can include the area under the skin on the abdomen, thighs, or upper arms.
Dosing of OXLUMO is based on the patient’s weight. Dosing happens in 2 phases:
-
The first 4 doses are taken a month apart. The first 3 are starting doses to help bring oxalate levels down. The 4th is the first ongoing dose and is given one month after the last starting dose.
-
Ongoing dosing is quarterly (every 3 months) or monthly, depending on the patient’s weight.
-
For children under 10 kg (22 lb), 1 DOSE EVERY MONTH
-
For patients weighing 10 kg (22 lb) or more, 1 DOSE EVERY 3 MONTHS
-
-
For patients on hemodialysis, OXLUMO will be administered after hemodialysis if administered on dialysis days.
The most common side effect of OXLUMO is injection site reaction (redness, swelling, pain, bruising, itching, discoloration at the site of injection).
-
- How can Alnylam Assist® help me?
-
Alnylam Assist® is here to help patients who are prescribed OXLUMO access treatment and learn more.
After you and your doctor decide to begin OXLUMO and enroll in Alnylam Assist®, we can provide support in 3 key areas
- Understanding Benefits
- Eligibility for Financial Assistance*
- Disease and Product Education
A trained Alnylam Patient Education Liaison (PEL)† is available to help you learn more about PH1 and OXLUMO. Visit the Alnylam Assist® website to learn more.
Individuals must meet specified criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.
Other resources and organizations
You and your family may find the following independent sites and organizations helpful.
We hope you find the resources mentioned here helpful. Alnylam Pharmaceuticals is not affiliated with these organizations. By listing these resources, Alnylam Pharmaceuticals is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided for informational purposes and should not replace your doctor’s medical advice.
CONNECT WITH AN ALNYLAM EDUCATOR
Learn about primary hyperoxaluria type 1 (PH1) and treatment with OXLUMO® from one of our trained Alnylam Patient Education Liaisons (PELs).
PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.
